Filing Flows › Bicycle Therapeutics (BCYC) › Q3 2026 › vs Q3 2025
Bicycle Therapeutics (BCYC) Q3 2026 vs Q3 2025 (year over year)
Bicycle Therapeutics's revenue rose $22.3M (+190%) from $11.7M in Q3 2025 to $34.1M in Q3 2026.
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $34.1M | $11.7M | $22.3M | +190% |
| Other income, net | $4.2M | $6.7M | −$2.5M | -37% |
| Net loss | $10.5M | $59.1M | −$48.6M | -82% |
| Costs & expenses | $48.7M | $77.5M | −$28.8M | -37% |
| Operating costs | $47.5M | $77.3M | −$29.8M | -38% |
| Income tax | $1.2M | $205K | $964K | +470% |
| Research & development | $33.4M | $58.4M | −$25.0M | -43% |
| General & admin | $14.1M | $18.9M | −$4.7M | -25% |
| Operating cash sources | $46.8M | $81.7M | −$34.9M | -43% |
| Depreciation & amortization | $1.1M | $1.8M | −$683K | -39% |
| Share-based compensation | $5.4M | $8.8M | −$3.4M | -38% |
| Cash used in operations | $40.3M | $71.2M | −$30.9M | -43% |
| Net loss absorbed | $10.5M | $59.1M | −$48.6M | -82% |
| Working capital & other | $36.3M | $22.6M | $13.7M | +61% |
Questions
How much did Bicycle Therapeutics's revenue grow year over year in Q3 2026?
Bicycle Therapeutics's revenue rose $22.3M (+190%) from $11.7M in Q3 2025 to $34.1M in Q3 2026.